- Trials with a EudraCT protocol (24)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
24 result(s) found for: Joint stability.
Displaying page 1 of 2.
EudraCT Number: 2006-004779-36 | Sponsor Protocol Number: BMTI-2006-03-EU | Start Date*: 2007-01-22 | |||||||||||
Sponsor Name:BioMimetic Therapeutic Inc | |||||||||||||
Full Title: A Human Clinical Trial to Evaluate the Safety and Clinical Utility of GEM OS1 as a Bone Regeneration System in Foot and Ankle Arthrodesis Procedures | |||||||||||||
Medical condition: For use as a bone void filler for voids or gaps that are not intrinsic to the stability of bony structure. Treatment of surgically created osseous defects or osseous defects resulting from patholo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000853-37 | Sponsor Protocol Number: SCH/07/006 | Start Date*: 2009-01-20 |
Sponsor Name:Sheffield Children's NHS Foundation Trust | ||
Full Title: Botulinum Toxin: an adjunct in limb reconstruction – can it reduce pain and joint complications in the lengthening phase? | ||
Medical condition: The surgery to correct leg & foot deformities in children is a lengthy, & sometimes, difficult procedure. Metal frames are attached to the leg and / or foot and over a period of time the frame is m... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-001545-25 | Sponsor Protocol Number: CHDR1409 | Start Date*: 2014-07-02 | ||||||||||||||||
Sponsor Name:Centre for Human Drug Research | ||||||||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying sys... | ||||||||||||||||||
Medical condition: Healthy volunteers (balance disorders) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003237-25 | Sponsor Protocol Number: POPPIV4.022.07.16 | Start Date*: 2015-08-21 |
Sponsor Name:University of Oxford | ||
Full Title: A blinded randomised placebo-controlled trial investigating the efficacy of morphine analgesia for procedural pain in infants | ||
Medical condition: Screening for Retinopathy of Prematurity is an essential yet painful routine test that is performed multiple times in infants who are born prematurely. Premature infants also regularly require heel... | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-005162-34 | Sponsor Protocol Number: clinical_study_protocol | Start Date*: 2017-05-19 | |||||||||||
Sponsor Name:University Hospital Basel | |||||||||||||
Full Title: Randomized, multi-center phase II clinical trial for the regeneration of cartilage lesions in the knee using nasal chondrocyte-based tissue (NTEC) or nasal chondrocyte-based cell (N-CAM)-therapies | |||||||||||||
Medical condition: Patients must display 1-2 symptomatic, focal cartilage lesion grade IIIIV (according to the grading by the International Cartilage Repair Society (ICRS)) from 2 to 8 cm2 on the femoral condyle and/... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005653-24 | Sponsor Protocol Number: IRB00003099 | Start Date*: 2021-06-28 |
Sponsor Name:Clínica Integral del pie-Ana Sans | ||
Full Title: Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology | ||
Medical condition: The application of Botox is described in the technical sheet for spasticity and has already been applied to the foot. This is how we speak of a phase IV clinical trial, with a low level of interven... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002668-29 | Sponsor Protocol Number: 132796 | Start Date*: 2020-06-25 |
Sponsor Name:University College London | ||
Full Title: A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX) | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2015-003332-13 | Sponsor Protocol Number: M13-549 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Dose of Conventional Synthetic Disease... | |||||||||||||
Medical condition: Moderately to Severely Active Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) ES (Completed) BG (Completed) CZ (Completed) DK (Completed) BE (Completed) IE (Completed) PT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) LV (Completed) FI (Completed) NO (Completed) LT (Completed) HU (Completed) GR (Completed) AT (Completed) RO (Completed) HR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002601-35 | Sponsor Protocol Number: ACT-2017-01 | Start Date*: 2018-07-02 |
Sponsor Name:PrimeCell Advanced Therapy a.s. | ||
Full Title: A Prospective, Randomized, Controlled, Multicenter, Phase II / III, Clinical Study to Evaluate the Effectiveness and Safety of NTC chondrograft® versus the Standard Procedure Arthroscopic Microfrac... | ||
Medical condition: Symptomatic knee articular cartilage defects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001725-27 | Sponsor Protocol Number: KKSH152 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | |||||||||||||
Full Title: A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses. | |||||||||||||
Medical condition: Postoperative pain therapy after implantation of a knee endoprosthesis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001028-23 | Sponsor Protocol Number: T1010-01 | Start Date*: 2017-08-02 | ||||||||||||||||
Sponsor Name:Tools4Patient | ||||||||||||||||||
Full Title: Validation Study to Investigate the Effect of T4P1010 treatment in Patients with Osteoarthritic Pain of Knee or Hip. | ||||||||||||||||||
Medical condition: Osteoarthritic pain of knee or hip. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004761-33 | Sponsor Protocol Number: CRO1881 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: A randomised double-blind placebo-controlled Phase 2B clinical trial of repeated application of gene therapy in patients with cystic fibrosis | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001008-23 | Sponsor Protocol Number: RIOP-1 | Start Date*: 2014-09-26 | |||||||||||
Sponsor Name:The Newcastle Upon Tyne Hospital NHS Foundation Trust, Freeman Hospital | |||||||||||||
Full Title: Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study | |||||||||||||
Medical condition: Pulmonary hypertension WHO Group III (Pulmonary hypertension owing to lung disease and/or hypoxia): Chronic obstructive pulmonary disease(COPD); Pulmonary Fibrosis (PF). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004215-30 | Sponsor Protocol Number: BRD/05/155 | Start Date*: 2006-02-24 |
Sponsor Name:Joint Sponsorship: University College London (UCL) & University College London Hospitals (UCLH) | ||
Full Title: Imaging the neural correlates of cholinergic and behaviour driven rehabilitation in patients with Wernicke’s aphasia: a double-blinded, cross-over, randomised controlled trial. | ||
Medical condition: Wernicke's aphasia caused by a stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001586-24 | Sponsor Protocol Number: | Start Date*: 2017-08-07 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: Delivering personalised care in the management of exacerbations of chronic obstructive pulmonary disease: A multi-centre randomised clinical trial | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006018-15 | Sponsor Protocol Number: 015K-CL-RA21 | Start Date*: 2012-07-28 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006020-20 | Sponsor Protocol Number: 015K-CL-RA22 | Start Date*: 2012-09-07 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis ... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005477-31 | Sponsor Protocol Number: I4C-MC-JTBC | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients with Acquired Resistance to Erlotinib | |||||||||||||
Medical condition: Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (Completed) BE (Completed) ES (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003315-35 | Sponsor Protocol Number: B7461006 | Start Date*: 2017-08-01 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc, | |||||||||||||||||||||||
Full Title: A Phase 3, randomized, open-label study of lorlatinib (PF-06463922) monotherapy versus crizotinib monotherapy in the first-line treatment of patients with advanced ALK-positive non-small cell lung ... | |||||||||||||||||||||||
Medical condition: Advanced ALK positive non small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) CZ (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003509-72 | Sponsor Protocol Number: 20200234 | Start Date*: 2021-10-21 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy | |||||||||||||
Medical condition: Active Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GR (Completed) PL (Prematurely Ended) AT (Completed) BG (Prematurely Ended) ES (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
